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T
his is the second of a series of arti-
cles based on presentations at the
AmericanDiabetesAssociation(ADA)
70th Scientiﬁc Sessions, held 25–29 June
2010inOrlando,Florida,pertainingtocar-
diovascular disease (CVD).
At a symposium on the relationship
between diabetes and CVD, Silvio E.
Inzucchi, New Haven,CT, reviewed ﬁnd-
ings of the Detection of Ischemia in
Asymptomatic Diabetes (DIAD) study.
Coronary artery disease (CAD) is a lead-
ing cause of morbidity and mortality,
but a concern is that myocardial ischemia
may be silent, with its ﬁrst presentation
an acute myocardial infarction or sudden
death. If CAD can be identiﬁed in a pre-
clinical stage, identifying patients with
silent ischemia might lead to beneﬁts
beyond that from intensive risk factor re-
duction,perhapsleadingto“moreserious”
risk factor treatment, both on the part of
thephysicianandonthepartofthepatient,
or, perhaps, to beneﬁts beyond that from
recommending revascularization. Screen-
ing can involve electrocardiographic exer-
cise testing, myocardial perfusion imaging
or stress echocardiography after adeno-
sineorexercise,orcomputedtomography
angiography.Therewerethreeportionsto
the DIAD study; the ﬁrst described the
prevalence and predictors of silent ische-
mia, the second identiﬁed which factors
were associated with progression and
w h i c hw i t hr e g r e s s i o no fC A D ,a n dt h e
third addressing the question of whether
cardiac event rates were affected by
screening versus not screening among in-
dividuals with type 2 diabetes.
With adenosine-sestamibi single
photon emission computed tomography
myocardial perfusion imaging (MPI),
DIAS endeavored to identify high-risk
patients based on conventional risk fac-
tors. The study included 1,123 eligible
type 2 diabetic patients age 50–75 years
without a history of CAD and with a nor-
malrestingelectrocardiogram,randomized
to undergo or not undergo MPI (1). Of
522 screened, 113 (22%) had abnormal-
ities, substantially fewer than the
50–60% anticipated, with 83 showing
perfusion abnormality, and 30 showed
electrocardiogramchangeorlunguptake
without perfusion abnormality. Among
those with perfusion abnormality, 50
were mild and 33 were moderate or
large,comprisingjust6%ofthescreened
cohort. Inzucchi pointed out that the
conventional risk factors typically used
to determine whether an individual
should be screened were not predictive
of abnormal MPI. This included ﬁndings
such as blood pressure, BMI, diabetes
duration, A1C, lipids, and C-reactive
protein (CRP) in univariate analysis, al-
though in multivariate analysis cardiac
autonomic neuropathy, diabetes dura-
tion, and male sex were predictive of
moderate-to-large defects. There were
no differences in prevalence of silent is-
chemia in those with ,2o r$2 risk fac-
tors (so, the ADA consensus statement
recommendation that only the latter be
screened appears to be incorrect). If silent
ischemia is not as common as previously
reported, if most of the perfusion defects
are small, and if baseline characteristics
are not predictive, a recommendation for
screening becomes difﬁcult to justify.
InthesecondpartofDIAD,358ofthe
522 screened individuals were included,
withtheotherslosttofollow-up.Ofthose
with MPI abnormalities on the initial
study, 79% had resolved, whereas in the
normal group ;10% became abnormal
(2). It appeared that the combination of
ACE inhibitors, statins, and aspirin was
associated with resolution of MPI defects,
suggesting the beneﬁt of current risk fac-
torreductionapproaches.Thequestionof
whether screening improved clinical out-
come was addressed in the third part of
the study (3). The observed CAD event
rate was 3% over 5 years, or 0.6% per
year, which is considerably less than the
traditional Framingham CVD equivalent
risk of.2%peryear (4). Asexpected,the
presence of perfusion defects did predict
events; other predictors were male sex,
peripheral arterial disease, LDL choles-
terol, serum creatinine, abnormal heart
rate response to standing, moderate-to-
large MPI defects, and nonperfusion ab-
normalities. Inzucchi commented, “The
surprise was that there was absolutely
no difference in clinical outcomes in the
screened versus not screened groups.” He
acknowledged that this was “al o w - r i s k
group of patients” and noted that partic-
ipantsinclinical trialstendto behealthier
but pointed out that they had an average
diabetes duration of 8 years and were
obese,that25%weretreatedwithinsulin,
that 60% had more than two risk factors,
and that 34% were not active at all and
50% were unable to exercise. A post hoc
analysis stratifying based on Framingham
Risk Score, UK Prospective Diabetes Study
(UKPDS) risk engine score, Association
de Langue Française pour l’Etude du Dia-
bète et des Maladies Métaboliques/Société
Française de Cardiologie (ALFEDIAM/
SFC)score(5),orthepresenceofmetabolic
syndrome showed no beneﬁto fs c r e e n i n g
in either the low-risk or the high-risk
groups. Inzucchi concluded that approxi-
mately one-ﬁfth of diabetic patients will
have CAD and that approximately one-
sixteenth will have major abnormalities
b u tt h a ti s c h e m i aa p p e a r sf r e q u e n t l yt o
resolve and that stress testing “does not
appeartofavorablyalteroutcomeratesin
thecontextofmodernpractice.”“Routine
screening,” he suggested, “cannot be rec-
ommended at this time.”
Siu et al. (abstract 869) reported from
the DIAD group that the baseline electro-
cardiogram showed axis deviation in5%, a
conduction defect in10%,and left ventric-
ularhypertrophyin2%;noneofthesewere
associated with MPI abnormality or with
development of acute coronary syndrome,
congestive heart failure (CHF), or cardiac
death. However, abnormal T-waves were
presentin14%,minorQwavesin10%,ST
depression in 4%, and ST elevation in 5%;
allwereassociatedwithdoublingorgreater
likelihood of MPI or clinical CAD events.
Kawasaki et al. (abstract 832) reported the
prevalence of CAD among 622 outpatients
and 573 inpatients with type 2 diabetes
without cardiac symptoms, undergoing
resting and treadmill electrocardiogram,
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PERSPECTIVES ON THE NEWSwith MPI based on these ﬁndings; only
1.4% of the 1,195 screened patients had
coronary angiography–proven CAD, cor-
roborating the DIAD ﬁndings. Jinnouchi
et al. (abstract 835) studied multidetector
computed tomography angiography of the
coronary arteries in 500 diabetic patients,
ﬁnding that 34% of those symptomatic
and 31% of those asymptomatic for CAD
had .75% stenosis. Kawai et al. (abstract
836) reported 64-slice multidetector com-
puted tomography angiography results in
140asymptomaticpatients,however,ﬁnd-
ing that 51% had evidence of signiﬁcant
coronary artery stenosis or calciﬁcation,
which occurred more often in those with
diabetes duration .11 years, hyperten-
sion, or increased carotid intima-media
thickness (IMT).
Bypass Angioplasty
Revascularization Investigation 2
Diabetes study
Darren K. McGuire, Dallas, TX, analyzed
the Bypass Angioplasty Revascularization
Investigation 2 Diabetes (BARI-2D) study
to review its ﬁndings on outcome of
revascularization versus medical therapy
for CAD. Diabetic patients comprise
one-third to one-half of subjects in car-
diovascular studies, with approximately
one-half not previously diagnosed (6,7),
“so not only is diabetes common, it is
probably much more common than pre-
viouslyrecognized”inpatientswithCVD,
and when not recognized or appropri-
ately treated it is particularly associated
with increased risk (8,9). McGuire re-
viewed evidence from the UKPDS of the
high prevalence of CAD, with fewer than
10% having a microvascular end point
but CVD during ;25% of the 40,000
patient-years of observation (10). He
suggested a number of treatment goals
once a diabetic patient develops CAD to
prolonglife;topreventmyocardialinfarc-
tion,CHF,arrhythmia,andangina;andto
optimizecost-efﬁciencyandavoidunnec-
essary procedures, particularly those re-
quiring hospitalization.
The original BARI study compared
coronary artery bypass graft (CABG) with
angioplasty, without stents or antiplatelet
treatment,andshowedthatinthediabetic
cohort CABG led to better survival than
percutaneous transluminal coronary
angioplasty (11), although this was a rel-
atively small population. Advances in
technology may, however, make these
ﬁndings obsolete. Intensiﬁed medical
treatment of lipids, blood pressure, and
glucose and better integrated systems to
improve adherence are available, as are
drug-eluting stents, closure devices, and
adjuvant therapies, and improvements in
CABG as well with greater use of arterial
conduits, improved glucose control, off-
pump options, and improved cardiople-
gia techniques require that clinical trial
ﬁndings be updated.
In BARI-2D, 2,368 patients were
randomized,allofwhomwerecandidates
for revascularization but who did not
immediately require the procedures be-
cause of unstable angina, to medical
treatment with or without intervention.
BaselineA1Cwas7.6%,diabetesduration
was 10 years, and approximately one-
third had a history of myocardial infarc-
tion and 10% cerebrovascular disease.
Revascularization had no beneﬁto v e r
optimal medical therapy in death, myo-
cardial infarction, or stroke. McGuire
pointed out that although 42% of the
medical group did cross over to revascu-
larization, because the majority conse-
quentially did not require such treatment
the choice not to operate or perform a
procedure should usually be considered
correct.
Overall, then, optimal medical treat-
ment is comparable to revascularization,
but it is noteworthy that in certain areas
CABGwaspreferable.Amongthoseinthe
percutaneous coronary intervention
(PCI) stratum, there was no beneﬁti n
death, myocardial infarction, or stroke,
although angina appears to have im-
proved. In fact, McGuire continued,
“we’ve never demonstrated that stents af-
fect event rates.” In the CABG stratum,
there was, however, reduction in myocar-
dial infarction and a trend to reduction in
death and stroke. The bypass group had
more advanced disease than those in the
PCI stratum, but the outlook of those un-
dergoing CABG became comparable with
that of those assigned to PCI.
Revascularization is challenging in
diabetes because of increased likelihood
of restenosis as well as accelerated ath-
erosclerosis beyond the target lesion.
There is a 40% greater likelihood of 30-
day mortality after CABG among individ-
uals with diabetes (12) and 80% greater
1-year mortality among diabetic patients
after PCI with 40% greater need for re-
vascularization (13). After 2 years, major
coronary events are more likely to occur
at sites different from that of the PCI, per-
haps explaining the beneﬁto fm o r et h o r -
ough vascular reconstruction with CABG
than that with PCI; another factor may be
greater clopidogrel resistance (14) and
greater likelihood of thrombosis of drug-
eluting stents (15) in diabetic patients.
The suggestion that bypass surgery is su-
perior is being prospectively tested in the
ongoing FREEDOM (Future REvascular-
ization Evaluation of patients with Diabe-
tes mellitus: Optimal management of
Multivessel disease) trial (16). For now,
however, McGuire concluded that in
this group, with a very high risk of events
(occurring annually in 4–5% of individu-
als randomized either to intervention or
to control in the BARI-2D study), “we
have a lot of work to do” in risk factor
reduction but must recognize that the
presence of an obstructive lesion does
not necessarily mean that revasculariza-
tion is required. Certainly, it is a concern
that only 47% of individuals in the trial
h a da nA 1 C,7% and only 71% had
blood pressure ,130/80 mmHg, al-
though 93% achieved LDL cholesterol
,100 mg/dL.
In a presentation at the ADA meeting,
Lavisetal.(abstract403)reportedoutcome
in insulin-treated patients in BARI-2D.
Overall,theresultsshowednoadvantage
of insulin-sensitizing over insulin-
providing treatment with sulfonylureas
or insulin with respect to mortality,
myocardial infarction, or stroke over 5
years. Those taking insulin at baseline
hadhigherratesofmortality,myocardial
i n f a r c t i o n ,C H F ,a n dh y p o g l y c e m i a ,a n d
their requirement for late revasculariza-
tionwastwiceasgreatasthatforsubjects
not taking insulin at baseline. Severe
hypoglycemia rates were more than twice
as great in these patients and were not
reduced with the insulin-sensitizing strat-
egy, as was the case in patients not taking
insulin at baseline.
Biomarkers and CVD
Peter W.F. Wilson, Atlanta, GA, dis-
cussed the use of biomarkers for CVD in
diabetes. How, he asked, do we incorpo-
rate novel biomarker information, recog-
nizing that “there’s a biomarker every
week” and that many will not be found
to be useful. In the assessment of a new
biomarker, the initial (and lowest cost)
approach is to perform a cross-sectional
study,analyzing itsassociationwith other
vascular risk factors or with subclinical
vascular disease such as carotid IMT or
coronary artery calciﬁcation (CAC). Be-
cause one needstotakeinto account mul-
tiple other conditions and parameters,
regression models are used, factoring in
age, sex, A1C,lipids, and many other var-
iables, hence, requiring a large study.
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studies, thousands of person-years of ob-
servation are required. To assess the pre-
dictive accuracy of a biomarker, Wilson
discussed the notion of discrimination/
reclassiﬁcation. Discrimination is mea-
sured with the C-statistic, the area under
thecurveofreceiveroperatingcharacter-
istic analysis, to deﬁne the ability of a
test to distinguish disease from nondi-
sease. Calibration refers to the ability
ofatesttomatchpredictedandobserved
outcome. Finally, he noted the impor-
tance of test characteristics, including
laboratory variability, biologic variabil-
ity, and cost. “Most tests as we have
done them over time,” Wilson pointed
out, “get cheaper and cheaper,” an argu-
m e n tf o ru s eo fo l d e rm a r k e r s .H o w e v e r ,
overtimesomemarkerswillbereplaced,
an example being the use of apolipopro-
tein B or non-HDL to replace LDL cho-
lesterol.
With such an approach to analysis of
tests, the increment in discrimination of
CRP and most other proposed markers is
minimal over that from existing measures
(17). It may, however, be optimal to add
several biomarkers in improving the dis-
criminationaccuracy.Inastudyusing the
Framingham data of new biomarker
determinants for CVD risk, B-type natri-
uretic peptide level, CRP, the urinary
albumin-to-creatinine ratio, homocys-
teine,andreninlevelspredicted mortality
and CVD events, with a panel of multiple
markers giving a small increase in overall
accuracy (18). Wilson commented that
although the improvement in test dis-
crimination was modest, such informa-
tion may be useful in other ways, with
natriuretic peptide indicating the prog-
nostic importance of CHF and the urine
albumin-to-creatinine ratio the impor-
tanceofchronickidneydisease.However,
there, too, older markers are usually suf-
ﬁcient to assess risk (19). Similar conclu-
sions apply to most new lipid markers,
such as small, dense LDL particle distri-
bution, which does not give better dis-
crimination than use of the LDL and
HDLcholesterollevels(20).Similar ques-
tions have been raised about whether use
of LDL particle number rather than LDL
and HDL cholesterol measurements is ef-
fective (21). Glycated albumin, CRP, and
tumor necrosis factor-a were associated
with severity of CAD in a study of type 2
diabetic individuals in Shanghai (22).
Otherstudieshaveinvestigatedadiponec-
tin, although Wilson did not ﬁnd this
convincing as a risk marker.
Wilson discussed the use of serial
testing for risk estimation/reclassiﬁcation
based on estimates of prior probability. A
test may be particularly important if its
use leads to reclassiﬁcation of an individ-
ual from, say, a 10–20% risk to a level
.20% or ,10%. Such an analysis per-
tains to the question of whether diabetic
patients are truly at high CAD risk in the
modern era of statins and blood pressure
and glycemic treatment. With such an
analysis, a study of 1,135 Swedish men
without CVD followed for a decade from
age 71 showed that adding natriuretic
peptide, CRP, and cystatin C did have
advantages in predicting CVD mortality
over the use of blood pressure, lipid, di-
abetes, cigarette, and obesity measures
(23). Another useful approach is to
validate a set of biomarkers in several
populations; with this approach, the
combination of troponin I, natriuretic
peptide, and CRP was associated with in-
creased risk (24).
Several studies have applied new
biomarkers for CAD risk prediction in
type1diabetes.Theuseofcarboxymethyl
lysine and soluble receptor for advanced
glycation end products was associated
with CVD in one study, but an evaluation
including all the standard risk factors was
not done, and Wilson suggested it likely
would not add to traditional markers. In
another study of type 1 diabetic individ-
uals with proteinuria, both CRP and
lipoprotein-associated phospholipase A2
were associated with risk (25).
Most data with all the biomarkers is
from cohorts that include both diabetic
and nondiabetic patients, and although
the new biomarkers provide information
about the pathophysiology of CVD, their
useinisolationfromtraditionalmarkers is
not very helpful, and the new biomarkers
appear unlikely to enhance CVD predic-
tion. Wilson suggested that a reasonable
strategy is to use diabetes factors, age, sex,
HDL and total cholesterol, cigarette use,
blood pressure, A1C, a measure of renal
function, albuminuria, and perhaps
greater consideration of markers of CHF.
A number of studies presented at the
ADA meeting discussed biomarkers and
CVD. Resl et al. (abstract 868) found that
among 308 diabetic patients, both base-
line and follow-up natriuretic peptide
levels were the most accurate predictors
of 29-month outcome when compared
with A1C, LDL cholesterol, microalbumi-
nuria, sex, duration of diabetes, and age.
Mori et al. (abstract 855) reported that
erythrocyte distribution width, which
reﬂectsthevariabilityinsizeofcirculating
erythrocytes, was associated with CVD
events andcarotid IMTand wasgreaterin
patients receiving sulfonylureas and
lower in those treated with thiazolidine-
diones. Vonbank et al. (abstract 858)
measured fasting insulin in 986 individ-
uals undergoing coronary angiography,
ﬁnding that homeostasis model assess-
ment (HOMA) of insulin sensitivity was
associated with metabolic syndrome but
not with CAD. Similarly, Kim et al. (ab-
stract 860) found that an insulin sensitiv-
ity index did not correlate with carotid
IMT, adjusting for age, sex, BMI, smok-
ing, systolic pressure, A1C, and HDL and
LDLcholesterol.Kimetal.(abstract793),
however, reported that lower levels of
HOMA of insulin sensitivity were associ-
ated with carotid IMT in a study of
876 nondiabetic healthy individuals.
In a study of type 1 diabetic patients,
Pambianco et al. (abstract 784) reported
that both cardiovascular autonomic neu-
ropathy and distal symmetrical polyneur-
opathy were associated with CHD and
mortality in an 18-year follow-up, al-
though neither was independently pre-
dictive in multivariate analysis. Waters
et al. (abstract 803) reported analysis of
1,433 diabetic individuals with stable
CADfollowedfor4.9years,ﬁndingmajor
CVD events in 19.5% of those with
baseline heart rate $70 bpm but in
13.6% of those with a lower heart rate.
Mortality increased 69% and likelihood
of CHF hospitalization increased 149%
in the more tacchycardic group, with dif-
ferences remaining after adjustment for
standard risk characteristics, suggesting
that heart rate should be considered an
independent risk factor. An interesting
observation by Takata et al. (abstract
295) was that postprandial glucose-
dependent insulinotrophic polypeptide
levels increased with increasing preva-
lence of hypertension and CVD in a co-
hort of 122 individuals after adjustment
for age, sex, smoking, BMI, postprandial
glucose, hypertension, and LDL choles-
terol. Son et al. (abstracts 806 and 833)
studied 174 type 2 diabetic individuals
without known CVD, ﬁnding bone mor-
phogenic protein-4 to correlate inversely
with carotidIMTafteradjustmentforage,
duration of diabetes, systolic blood pres-
sure, BMI, A1C, lipid proﬁles, and CRP.
Limits of glycemic control in
reducing CVD
Peter D. Reaven, Phoenix, AZ, addressed
the question of whether the beneﬁto f
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microvascular and macrovascular disease
might be outweighed by negative effects,
particularly in the presence of CVD,
hypoglycemia, and weight gain. Further,
he suggested the concept of “vascular
age,” which may limit the ability of glyce-
mic control to improve outcome. In the
DiabetesControlandComplicationsTrial
in younger type 1 diabetic patients and in
the Kumamoto and UKPDS studies of
type 2 diabetic patients, all microvascular
end points decreased, while CVD out-
comes“werelessclear,”althoughposttrial
follow-up of both the DCCT (26,27) and
UKPDS(28),despite lossofglycemicsep-
aration, did show CVD beneﬁt, leading to
theconceptofmetabolicmemory.Reaven
askedwhethertheremaybe“negativegly-
cemic memory of poor glycemic control”
of diabetes. The Action to Control Car-
diovascular Risk in Diabetes (ACCORD)
trial, Action in Diabetes and Vascular Dis-
ease: Preterax and Diamicron MR Con-
trolled Evaluation (ADVANCE) trial, and
Veterans Affairs Diabetes Trial (VADT)
endeavored to assess cardiovascular ef-
fects of glycemic control. The intensively
treated group in ACCORD had increased
mortality, although subset analysis
showed that individuals without CVD
and those with A1C ,8% at entry had
evidence of reduction in the primary car-
diovascular outcome. In ADVANCE,
there was no overall macrovascular bene-
ﬁt in an older population with a high
prevalence of CVD. In the VADT, A1C
separation was 6.9 vs. 8.4%, but the re-
duction in composite CVD outcome was
not signiﬁcant. Post hoc analysis showed
that diabetes duration was related to ben-
eﬁt, with a 0–15 year hazard ratio (HR) of
0.74 but a $16 year HR of 1.24 in CVD
outcome. “Intensive glycemic control
does not come without a cost,” Reaven
said: athreefold increasein hypoglycemia
in the VADT, and severe and recent hy-
poglycemia was a very important predic-
tor of cardiovascular death in the study.
A meta-analysis including ACCORD,
ADVANCE, UKPDS, and VADT showed
asi gn i ﬁcant9%reduction inmajormacro-
vascular events, but those with a history
eitherofmacrovascularorofmicrovascular
disease did not beneﬁt (29). Reaven re-
called theﬁndingsoftheDiabetesMellitus,
InsulinGlucoseInfusioninAcuteMyocar-
dial Infarction (DIGAMI) study of 620
diabetic individuals allocated to intensive
insulin after myocardial infarction, pre-
randomized into four groups based on
risk. Only the low-risk subgroup not
treated with insulin, and without CAD
history, had beneﬁt (30). Glucose lower-
ing among newly detected diabetic pa-
tients with glycemic treatment in the
Euro Heart Survey suggested beneﬁti n
reducing mortality (31). Similarly, in a
5-year follow-up of type 2 diabetic pa-
tients,thosewithahighcomorbidityscore
whohadlowerA1Cdidnotdobetterthan
those with higher A1C, but with a low
comorbidity score, lower A1C was associ-
ated with better outcome (32).
Another approach is to directly assess
the level of atherosclerosis burden; this
approach was taken in a VADT substudy,
with CAC measured at onset and at 5
years (33). Those with lower CAC had
evidence of better cardiovascular out-
come with intensive glycemic treatment,
but with higher CAC glycemic treatment
did not produce cardiovascular beneﬁt,
which Reaven interpreted as “suggesting
perhaps that if you have ...extensivedis-
ease you are less well able to respond.”
The follow-up of CAC showed that less
progression occurred in individuals with
lower baseline CAC scores (34).
“We don’t exactly understand,”
Reaven commented, why poor prior gly-
cemic control would be associated with
less beneﬁt of improved control during
the study. A suggestion has been ad-
vanced that “y o um a yn o tb ea b l et oo v e r -
come” advanced glycemic end product
protein cross-linking, lesion necrosis, ex-
cess mitochondrial reactive oxidant stress
and damage, glycemia-induced renal
disease, vasa vasorum angiogenesis, ex-
panded vascular smooth muscle, or epi-
genetic changes in gene transcription
occurringwithlong-standinghyperglyce-
mia (35). A study of the effect of prior
control in type 1 diabetic patients with
new onset, those with diabetes for 5 years
with mean A1C ,7%, and those with di-
abetes for 5 years with mean A1C .7%
foundimprovement inﬂow-mediated va-
sodilation when normal glucose levels
were maintained only in the former two
groups (36), further suggesting the exis-
tence of this adverse effect of poor glyce-
mic control.
Reaven concluded that optimal A1C
should be individualized based on the
patient’s risk for and from hypoglycemia,
their potential for beneﬁto fl o w e rA 1 C ,
thedifﬁcultyofattainingcontrol,andvas-
cular age based on prior CVD and long
diabetes duration (37). With none of
these factors, an A1C of 6.5–7% may be
appropriate; with one factor, the goal
m i g h tb e7 . 5 % ;a n dw i t ht w oo rm o r e
factors, a goal of 7.5–8% might be most
appropriate.
Is diabetes a CVD risk equivalent?
Atadebateonwhetherdiabetesshouldbe
considered a cardiovascular disease
equivalent, Eberhard Standl, Munich,
Germany, argued in the afﬁrmative, al-
though admitting that “we do not know
the ultimate answer.” The concept began
with the East-West study ﬁndings (38)
suggesting that diabetic patients without
CAD history had risk levels similar to
those of nondiabetic individuals with a
history of myocardial infarction. A meta-
analysis of this and 12 other studies
showed, however, that there were lower
CAD rates in individuals with diabetes
than in those with a history of myocardial
infarction (39). Standl noted, however,
that the investigators excluded .300
other papers on the topic for various rea-
sons, leading one to be uncertain as to
whether the analysis could have been car-
ried out in a different fashion. Examples
of the omitted studies (which would have
supported the CAD equivalent argument)
include a population study of 3.3 million
individuals in Denmark showing that di-
abetic patients requiring glucose-lowering
treatment had the same cardiovascular
risk as nondiabetic individuals with a
prior myocardial infarction (40); a study
of .9 million individuals living in On-
tario, Canada (41); and an update of the
original East-West study population con-
tinuing to show increased risk in diabetic
individuals (42). Standl suggested, then,
thatthereareimportantandcontradictory
data missing and that there is certainly
evidence that CAD risk is high in diabetic
patients. Further, Standl noted that if di-
abetes is considered a CAD equivalent
then no expensive screening is needed.
There has been evidence for a long time
of a high prevalence of CAD in diabetic
individuals (43). A concern is, however,
that the Framingham and UKPDS risk
equations may be inaccurate and may
overestimate risk in diabetic individuals
(44–46). Particular underestimation of
cardiovascular risk occurs among individ-
ualsatlowerrisk,withdiabetesamplifying
the adverse effects of metabolic syndrome
(47).
Further evidence comes from studies
of both type 1 and type 2 diabetic
individuals for several decades. Standl
pointed out that over the ﬁrst 5 years of
diabetes, thereis little evidence of adverse
outcome (48). Furthermore, he stated,
20–35% of diabetic individuals without
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cardial ischemia (43), as conﬁrmed in the
DIAD study (described above), and silent
myocardial ischemia is associated with a
10-year risk of ;30%. Of further note are
studies of 5-year outcomes in 8,357 Aus-
tralian individuals (49) and in the 9,306-
person Nateglinide and Valsartan in
Impaired Glucose Tolerance Outcomes
Research (NAVIGATOR) trial (50)
suggesting a dose-effect relationship be-
tween the degree of hyperglycemia and
CVD outcome. In ADVANCE, the total
population without prior macrovascular
disease history was 7,502 individuals
and their estimated 10-year CVD risk
was 33%, with 15% major CVD, 14%
CAD, and 8% major CAD (not including
CHF) risks (44). Those without a history
of macrovascular disease in VADT,
ACCORD, and ADVANCE had 10-year
risks of CAD events of ;18%, Standl
stated, despite unusually good control of
blood pressure and lipids. He noted that
the DIAD study suggests it is not neces-
sary to screen for silent myocardial ische-
mia and that multifactorial therapy was
appropriate, with evaluation if symptoms
occur. Similar conclusions can be drawn
from the Clinical Outcomes Using Revas-
cularization and Aggressive Drug Evalua-
tion (COURAGE) trial, in which 33% of
enrolled patients had diabetes (51) and
BARI-2D (discussed above), leading
Standl to conclude that individuals with
diabetes arestillat high CAD risk (around
15–20%at10years),withCVDprognosis
markedly improved by intensive multi-
factorial treatment. Studies such as
DIAD suggest that screening does not
change prognosis, which underscores
the importance of regarding diabetic pa-
tients as requiring aggressive medical
treatment.
Iskandar R. Idris, Shefﬁeld, U.K.,
took the contrary position, that diabetes
is not really a cardiovascular risk equiva-
lent, while recognizing that it is a major
risk factor for developing CVD (52) and
that after myocardial infarction, diabetes
increases risk (53). The question is
whetherdiabetesisaCADriskequivalent,
which would mean 10-year risk for major
coronary events .20%. This would im-
ply, Idris stated, a need for statins in al-
most all patients. Further, he pointed out
that the 10-year 20% CAD risk applies to
individuals with stable angina and that
those with major CAD have a 10-year
risk of 26%, while most studies show
that risk levels are lower with diabetes
(54). He compared a high-risk strategy
of “treating the most needy” with a “pop-
ulation strategy,” in which a whole pop-
ulation receives treatment, suggesting the
former to be more beneﬁcial (55). In the
Strong Heart Study, Idris stated, diabetes
alone was consistently a lesser risk factor
than CAD alone, although diabetes with
multiple risk factors was associated with
much higher risk, particularly with dia-
betic dyslipidemia. He pointed out that
in the East-West study, patients were
self-selected and had pharmacologically
treated diabetes. Other studies suggesting
that diabetes may not be equivalent to
CAD are the Nurses’ Health Study
(56), a prospective cohort study of U.S.
physicians (57), and the Atherosclerosis
Risk in Communities study (58). In one
of the studies cited by Standl, Idris stated,
at above age 50 years the CAD mortality
riskbecamesimilarfordiabetesalonever-
sus prior CVD in males, but not in fe-
males, andwasinterpretedby the authors
to suggest that diabetes did not convey
risk equivalent to CAD but, rather, could
be equated with 15 years of aging (41).
His similar study in the U.K. primary
care cohort suggests that the age of tran-
sition from low to high risk was approx-
imately 52 years in men and 49 years in
women (54), but in Asian Indian patients
theageswere37and50years,respectively
(59). He reviewed his meta-analysis, as
previously discussed by Standl, and ex-
plained that it showed that patients with
diabetes without prior CVD had signiﬁ-
cantly lower risk than patients with prior
myocardial infarction without diabetes
(39). Diabetes as a true CVD equivalent
would require routine use of aspirin, clo-
pidogrel, ACE inhibitors or angiotensin
receptor blockers, b-blockers, and high-
dose statins, but evidence to justify this
is lacking. Furthermore, risk reduction in
patients with diabetes in lipid-lowering
trials is similar to that in nondiabetic pa-
tients, also suggesting little speciﬁca d -
verse effect of diabetes. Idris concluded
that there is signiﬁcant heterogeneity in
cardiovascular risk among diabetic pa-
tients, that a primary prevention strategy
topreventCVDindiabeticpatientsshould
be based on individual risk assessment,
and that the blanket statement of diabetes
as a cardiovascular risk equivalent is un-
proven and, perhaps, unhelpful.
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